Phase 2 Lymphoma Trial, Recruiting (NCT06608342)

Phase 2 Lymphoma Trial, Recruiting NCT06608342 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06608342 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults diagnosed with a high-risk form of acute B-cell leukemia (a type of blood cancer)
People whose leukemia went into remission (cancer became undetectable) after initial chemotherapy, and for whom a special personalised immune cell treatment called CAR-T has been successfully made from their own cells
People whose health is considered suitable for a procedure to collect and transplant their own blood stem cells
People without serious problems affecting major organs such as the heart, lungs, liver, or kidneys

Who may not be able to join:

People who also have another type of cancer in a different part of the body
People who have a serious active infection that has not been brought under control
People who test positive for syphilis, HIV/AIDS, hepatitis B, or hepatitis C
People who have previously had an allergic reaction to the medicines used in this trial or to similar medicines
People the trial doctors consider unsuitable for participation for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-15122538106

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06608342

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

Trial contact: +86-15122538106

More information: https://clinicaltrials.gov/study/NCT06608342

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults diagnosed with a high-risk form of acute B-cell leukemia (a type of blood cancer)
People whose leukemia went into remission (cancer became undetectable) after initial chemotherapy, and for whom a special personalised immune cell treatment called CAR-T has been successfully made from their own cells
People whose health is considered suitable for a procedure to collect and transplant their own blood stem cells
People without serious problems affecting major organs such as the heart, lungs, liver, or kidneys

Who may not be able to join:

People who also have another type of cancer in a different part of the body
People who have a serious active infection that has not been brought under control
People who test positive for syphilis, HIV/AIDS, hepatitis B, or hepatitis C
People who have previously had an allergic reaction to the medicines used in this trial or to similar medicines
People the trial doctors consider unsuitable for participation for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Registry

ClinicalTrials.gov

Start date

25 June 2024

Est. completion

30 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Relapse rate within 2 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov